0NF0 Stock Overview
Mydecine Innovations Group Inc., a biotechnology company, engages in the development and commercialization of psilocybin products for treating mental health problems.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Mydecine Innovations Group Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.01 |
52 Week High | US$0.29 |
52 Week Low | US$0.0005 |
Beta | 3.2 |
1 Month Change | 1,900.00% |
3 Month Change | 81.82% |
1 Year Change | -96.32% |
3 Year Change | -99.93% |
5 Year Change | -99.97% |
Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
0NF0 | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | -33.3% | 1.9% | 1.2% |
1Y | -96.3% | -28.2% | 2.0% |
Return vs Industry: 0NF0 underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 0NF0 underperformed the German Market which returned 2% over the past year.
Price Volatility
0NF0 volatility | |
---|---|
0NF0 Average Weekly Movement | 749.5% |
Pharmaceuticals Industry Average Movement | 6.6% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 0NF0's share price has been volatile over the past 3 months.
Volatility Over Time: 0NF0's weekly volatility has increased from 630% to 749% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 3 | Josh Bartch | www.mydecine.com |
Mydecine Innovations Group Inc., a biotechnology company, engages in the development and commercialization of psilocybin products for treating mental health problems. The company primarily focuses on treating smoking cessation. Its lead product drug candidates include MYCO-001, MYCO-002, MYCO003, and MYCO-004.
Mydecine Innovations Group Inc. Fundamentals Summary
0NF0 fundamental statistics | |
---|---|
Market cap | €1.27m |
Earnings (TTM) | -€12.35m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs 0NF0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0NF0 income statement (TTM) | |
---|---|
Revenue | CA$0 |
Cost of Revenue | CA$0 |
Gross Profit | CA$0 |
Other Expenses | CA$18.07m |
Earnings | -CA$18.07m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.29 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | -84.4% |
How did 0NF0 perform over the long term?
See historical performance and comparison